ATE503476T1 - Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind - Google Patents

Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind

Info

Publication number
ATE503476T1
ATE503476T1 AT05812101T AT05812101T ATE503476T1 AT E503476 T1 ATE503476 T1 AT E503476T1 AT 05812101 T AT05812101 T AT 05812101T AT 05812101 T AT05812101 T AT 05812101T AT E503476 T1 ATE503476 T1 AT E503476T1
Authority
AT
Austria
Prior art keywords
methods
infection
treatment
compositions
diseases caused
Prior art date
Application number
AT05812101T
Other languages
English (en)
Inventor
Tomas Mustelin
Maurizio Pellecchia
Lutz Tautz
Original Assignee
Burnham Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst filed Critical Burnham Inst
Application granted granted Critical
Publication of ATE503476T1 publication Critical patent/ATE503476T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05812101T 2004-10-21 2005-10-19 Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind ATE503476T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62144204P 2004-10-21 2004-10-21
PCT/US2005/037537 WO2006047162A2 (en) 2004-10-21 2005-10-19 Compositions and methods for treatment of disease caused by yersinia spp infection

Publications (1)

Publication Number Publication Date
ATE503476T1 true ATE503476T1 (de) 2011-04-15

Family

ID=36228235

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05812101T ATE503476T1 (de) 2004-10-21 2005-10-19 Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind

Country Status (5)

Country Link
US (1) US20090312352A1 (de)
EP (1) EP1802297B1 (de)
AT (1) ATE503476T1 (de)
DE (1) DE602005027228D1 (de)
WO (1) WO2006047162A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939554B2 (en) 2006-06-28 2011-05-10 The Cleveland Clinic Foundation Protein phosphatase inhibitors
AU2016225942B2 (en) * 2011-01-26 2017-08-31 Board Of Regents Of The University Of Nebraska Small molecule RNase inhibitors and methods of use
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
WO2015127125A1 (en) 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
ES2639863B1 (es) * 2017-03-10 2018-09-20 Universidad De Granada Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185021A (en) * 1979-02-12 1980-01-22 Morton-Norwich Products, Inc. 5-(p-Nitrophenyl)-2-furaldehyde 2-(2-hydroxyethyl)hydrazone
WO2000013708A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
US20020091148A1 (en) * 2000-09-15 2002-07-11 Bamaung Nwe Y. 3-substituted indole antiproliferative angiogenesis inhibitors
US20020052396A1 (en) * 2001-04-23 2002-05-02 Bailey Thomas R. Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
GB2376944A (en) * 2001-05-18 2002-12-31 Pantherix Ltd Polycyclic heterocyclic compounds and their therapeutic use
US20050042674A9 (en) * 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
US7713981B2 (en) * 2002-02-28 2010-05-11 University Of Central Florida Method and compounds for inhibition of cell death
AU2003225668A1 (en) * 2002-03-01 2003-09-16 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
US20040180889A1 (en) * 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
GB2386892A (en) * 2002-03-28 2003-10-01 Pantherix Ltd Carboxy containing (phenyl-/heterocyclyl-)methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
US20060281798A1 (en) * 2002-05-17 2006-12-14 Qlt Inc. Methods of using thiazolidinedithione derivatives
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
DE602004025708D1 (de) * 2003-07-11 2010-04-08 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
FR2858324A1 (fr) * 2003-07-30 2005-02-04 Centre Nat Rech Scient Nouveaux composes antibiotiques, compositions pharmaceutiques les contenant et leurs utilisations
EP1718308A4 (de) * 2004-02-11 2007-07-18 Painceptor Pharma Corp Verfahren zur modulierung der neurotrophin-vermittelten aktivität

Also Published As

Publication number Publication date
EP1802297B1 (de) 2011-03-30
DE602005027228D1 (de) 2011-05-12
EP1802297A2 (de) 2007-07-04
WO2006047162A3 (en) 2006-09-21
US20090312352A1 (en) 2009-12-17
EP1802297A4 (de) 2008-05-28
WO2006047162A2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
EA200601239A1 (ru) Замещённые хинолиновые соединения
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA200802213A1 (ru) Способы лечения заболеваний крови
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA201070247A1 (ru) Ингибиторы протеасом
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA200801565A1 (ru) Производные пиримидиниларилмочевины в качестве ингибиторов фактора роста фибробластов ( fgf-фактора )
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
EA200600588A1 (ru) Соединения, содержащие галоидалкил, как ингибиторы цистеиновых протеаз
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
EA200900783A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA200900900A1 (ru) Производные замещенных 3-фенил-1-(фенилтиенил)пропан-1-онов и 3-фенил-1-(фенилфуранил)пропан-1-онов, их получение и применение
ATE555131T1 (de) Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
DE602004020042D1 (de) er SSRI zur Behandlung von Stimmungs- oder Angststörungen
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties